Table 4.
Multivariate Cox regression analysis of survival related to coexpression of CD155 and TME biomarkers adjusted for clinicopathologic features1.
| Variables | Multivariate analysis | P |
|---|---|---|
| HR (95% CI) | ||
| Clinicopathologic features + CD155 | 1.160 (0.795-1.694) | 0.442 |
| Clinicopathologic features + CD155/CD3 | 1.500 (1.028-2.188) | 0.036 |
| Clinicopathologic features + CD155/CD4 | 1.488 (1.019-2.173) | 0.040 |
| Clinicopathologic features + CD155/CD8 | 1.378 (0.945-2.007) | 0.096 |
| Clinicopathologic features + CD155/Foxp3 | 1.429 (0.985-2.072) | 0.060 |
| Clinicopathologic features + CD155/IL-17 | 1.208 (0.825-1.767) | 0.331 |
| Clinicopathologic features + CD155/IFN-γ | 1.337 (0.908-1.970) | 0.141 |
| Clinicopathologic features + CD155/CD19 | 1.565 (1.072-2.286) | 0.020 |
| Clinicopathologic features + CD155/CD11c | 1.321 (0.896-1.948) | 0.160 |
| Clinicopathologic features + CD155/CD56 | 0.983 (0.673-1.436) | 0.929 |
| Clinicopathologic features + CD155/CD68 | 1.009 (0.683-1.491) | 0.964 |
| Clinicopathologic features + CD155/CD31 | 0.946 (0.630-1.420) | 0.789 |
| Clinicopathologic features + CD155/α-SMA | 1.344 (0.909-1.988) | 0.138 |
1Clinicopathologic features include tumor volume, tumor stage, tumor depth, lymph node involvement and metastasis (Statistically significant in Table 3 ).